◆ Market Data --:--
Commodities
Loading...
📈 Yields & Rates
Loading...
💱 FX Rates
Loading...
📈 Market Pulse
Loading...
🏛 Congress Trades
Loading...
👤 Insider Trades
Loading...

Crescita Therapeutics Inc.

Financial Statements (IFRS) · Amounts in CAD
5 10 All
Income Statement
Balance Sheet
Cash Flow
Line Item Q3 2025Sep 30, 2025 Q2 2025Jun 30, 2025 Q1 2025Mar 31, 2025 Q4 2024Dec 31, 2024 Q3 2024Sep 30, 2024 Q2 2024Jun 30, 2024
Total Revenue 5.4M 6.2M 3.5M 6.9M 3.6M --
Operating Revenue 5.4M 6.2M 3.5M 6.9M 3.6M --
Cost Of Revenue 2.5M 2.4M 1.8M 3.9M 1.6M --
Gross Profit 2.9M 3.8M 1.7M 3.0M 2.0M --
Selling General And Administration 2.5M 2.7M 2.3M 2.7M 2.7M --
General And Administrative Expense -- 2.7M -- -- -- 2.8M
Research And Development 138,000 141,000 131,000 156,000 157,000 --
Depreciation And Amortization In Income Statement 384,000 353,000 353,000 365,000 312,000 --
Operating Expense 3.0M 3.2M 2.8M 3.3M 3.1M --
Operating Income -162,000 583,000 -1.1M -268,000 -1.2M --
EBIT 763,000 810,000 -920,000 -161,000 -1.0M --
Interest Expense 10,000 12,000 12,000 15,000 15,000 --
Interest Expense Non Operating 10,000 12,000 12,000 15,000 15,000 --
Interest Income 38,000 131,000 100,000 134,000 111,000 --
Interest Income Non Operating 38,000 131,000 100,000 134,000 111,000 --
Net Interest Income 28,000 119,000 88,000 119,000 96,000 --
Other Income Expense 887,000 96,000 42,000 -27,000 40,000 --
Other Non Operating Income Expenses 1.5M -- -- -- -- --
Special Income Charges -281,000 -- -- -- 0.00 --
Write Off 281,000 -- -- -- 0.00 --
Gain On Sale Of Security -289,000 100,000 56,000 17,000 36,000 --
Earnings From Equity Interest -12,000 -4,000 -14,000 -44,000 4,000 --
Pretax Income 753,000 798,000 -932,000 -176,000 -1.0M --
Tax Provision -- -- -- -14,000 0.00 0.00
Tax Effect Of Unusual Items -85,500 15,000 0.00 1,352 0.00 --
Net Income From Continuing And Discontinued Operation 753,000 798,000 -932,000 -162,000 -1.0M --
Net Income From Continuing Operation Net Minority Interest 753,000 798,000 -932,000 -162,000 -1.0M --
Net Income Including Noncontrolling Interests 753,000 798,000 -932,000 -162,000 -1.0M --
Net Income Common Stockholders 753,000 798,000 -932,000 -162,000 -1.0M --
Net Income 753,000 798,000 -932,000 -162,000 -1.0M --
EBITDA 1.1M 1.2M -567,000 204,000 -709,000 --
Normalized EBITDA 1.7M 1.1M -623,000 187,000 -745,000 --
Reconciled Depreciation 384,000 353,000 353,000 365,000 312,000 --
Basic EPS 0.04 0.04 -0.05 -- -0.05 -0.05
Diluted EPS 0.04 0.04 -0.05 -- -0.05 -0.05
Basic Average Shares 18.8M 18.9M 19.0M -- 19.3M 19.4M
Diluted Average Shares 18.8M 19.0M 19.0M -- 19.3M 19.4M
Total Unusual Items -570,000 100,000 56,000 17,000 36,000 --
Total Unusual Items Excluding Goodwill -570,000 100,000 56,000 17,000 36,000 --
Tax Rate For Calcs 0.15 0.15 0.00 0.08 0.00 --
Normalized Income 1.2M 713,000 -988,000 -177,648 -1.1M --
Depreciation Amortization Depletion Income Statement 384,000 353,000 353,000 365,000 312,000 --
Diluted NI Availto Com Stockholders 753,000 798,000 -932,000 -162,000 -1.0M --
Net Income Continuous Operations 753,000 798,000 -932,000 -162,000 -1.0M --
Net Non Operating Interest Income Expense 28,000 119,000 88,000 119,000 96,000 --
Other Gand A -- 1.4M -- -- -- 1.4M
Reconciled Cost Of Revenue 2.5M 2.4M 1.8M 3.9M 1.6M --
Salaries And Wages -- 1.3M -- -- -- 1.4M
Total Expenses 5.6M 5.7M 4.6M 7.2M 4.8M --
Total Operating Income As Reported -162,000 583,000 -1.1M -268,000 -1.2M --
Line Item Q3 2025Sep 30, 2025 Q2 2025Jun 30, 2025 Q1 2025Mar 31, 2025 Q4 2024Dec 31, 2024 Q3 2024Sep 30, 2024 Q2 2024Jun 30, 2024
Cash And Cash Equivalents 8.3M 8.2M 8.5M 9.3M 8.4M --
Cash Cash Equivalents And Short Term Investments 8.3M 8.2M 8.5M 9.3M 8.4M --
Accounts Receivable 1.7M 2.1M 1.5M 1.4M 1.1M --
Receivables 1.9M 2.3M 1.6M 1.7M 1.3M --
Inventory 5.4M 4.9M 5.1M 4.1M 6.1M --
Prepaid Assets -- -- -- 264,000 -- --
Other Current Assets 403,000 394,000 344,000 -- 445,000 454,000
Current Assets 16.0M 15.8M 15.5M 15.3M 16.3M --
Gross PPE 2.1M 2.3M 2.3M 5.0M 2.3M --
Accumulated Depreciation -- -- -- -2.5M -- --
Net PPE 2.1M 2.3M 2.3M 2.4M 2.3M --
Goodwill And Other Intangible Assets 1.6M 1.4M 1.6M 1.7M 1.9M --
Other Intangible Assets -- -- -- 1.7M -- --
Investments And Advances 0.00 293,000 297,000 311,000 355,000 --
Long Term Equity Investment 0.00 293,000 297,000 311,000 355,000 --
Total Non Current Assets 5.5M 6.1M 6.2M 6.5M 6.4M --
Total Assets 21.5M 21.9M 21.8M 21.8M 22.7M --
Current Debt And Capital Lease Obligation 484,000 479,000 474,000 469,000 453,000 --
Payables And Accrued Expenses 4.6M 5.5M 6.0M 5.0M 5.5M --
Other Current Liabilities 50,000 50,000 50,000 50,000 50,000 --
Current Liabilities 5.1M 6.1M 6.6M 5.5M 6.0M --
Long Term Debt And Capital Lease Obligation 0.00 123,000 244,000 365,000 473,000 --
Long Term Capital Lease Obligation 0.00 123,000 244,000 365,000 473,000 --
Other Non Current Liabilities 79,000 75,000 71,000 67,000 112,000 --
Total Non Current Liabilities Net Minority Interest 79,000 198,000 315,000 432,000 585,000 --
Total Liabilities Net Minority Interest 5.2M 6.3M 6.9M 5.9M 6.6M --
Common Stock 51.5M 52.2M 52.5M 52.7M 53.0M --
Capital Stock 51.5M 52.2M 52.5M 52.7M 53.0M --
Additional Paid In Capital 8.4M 7.8M 7.6M 7.4M 7.1M --
Retained Earnings -44.7M -45.5M -46.3M -45.3M -45.2M --
Gains Losses Not Affecting Retained Earnings 1.1M 1.1M 1.1M 1.1M 1.1M --
Other Equity Adjustments 1.1M 1.1M 1.1M 1.1M 1.1M --
Common Stock Equity 16.3M 15.6M 14.9M 15.8M 16.1M --
Stockholders Equity 16.3M 15.6M 14.9M 15.8M 16.1M --
Total Equity Gross Minority Interest 16.3M 15.6M 14.9M 15.8M 16.1M --
Total Capitalization 16.3M 15.6M 14.9M 15.8M 16.1M --
Net Tangible Assets 14.6M 14.2M 13.3M 14.1M 14.2M --
Tangible Book Value 14.6M 14.2M 13.3M 14.1M 14.2M --
Working Capital 10.9M 9.7M 9.0M 9.8M 10.2M --
Invested Capital 16.3M 15.6M 14.9M 15.8M 16.1M --
Total Debt 484,000 602,000 718,000 834,000 926,000 --
Share Issued 18.6M 18.9M 19.0M 19.1M 19.2M --
Ordinary Shares Number 18.6M 18.9M 19.0M 19.1M 19.2M --
Allowance For Doubtful Accounts Receivable -92,000 -92,000 -92,000 -92,000 -47,000 --
Capital Lease Obligations 484,000 602,000 718,000 834,000 926,000 --
Current Capital Lease Obligation 484,000 479,000 474,000 469,000 453,000 --
Finished Goods 3.2M 2.5M 3.1M 2.5M 2.8M --
Gross Accounts Receivable 1.8M 2.2M 1.6M 1.4M 1.1M --
Investmentsin Associatesat Cost 0.00 293,000 297,000 311,000 355,000 --
Leases -- -- -- 617,000 -- --
Machinery Furniture Equipment -- -- -- 891,000 -- --
Non Current Accounts Receivable 1.4M 1.4M 1.4M 1.4M 1.4M --
Non Current Note Receivables 300,000 649,000 622,000 614,000 458,000 --
Other Properties 2.1M 2.3M 2.3M 3.5M 2.3M --
Other Receivables 184,000 120,000 61,000 226,000 170,000 --
Properties -- -- -- 0.00 -- --
Raw Materials 1.5M 2.1M 1.6M 984,000 2.6M --
Taxes Receivable -- -- -- 133,000 -- --
Work In Process 687,000 373,000 473,000 564,000 755,000 --
Line Item Q3 2025Sep 30, 2025 Q2 2025Jun 30, 2025 Q1 2025Mar 31, 2025 Q4 2024Dec 31, 2024 Q3 2024Sep 30, 2024 Q2 2024Jun 30, 2024
Operating Cash Flow 1.2M -3,000 -513,000 1.4M 424,000 --
Cash Flow From Continuing Operating Activities 1.2M -3,000 -513,000 1.4M 424,000 --
Depreciation And Amortization 384,000 353,000 353,000 365,000 312,000 --
Depreciation Amortization Depletion 384,000 353,000 353,000 365,000 312,000 --
Stock Based Compensation 7,000 28,000 30,000 17,000 89,000 --
Deferred Tax -- -- -- -14,000 0.00 0.00
Deferred Income Tax -- -- -- -14,000 0.00 0.00
Change In Working Capital 706,000 -1.1M 146,000 1.1M 1.0M --
Changes In Account Receivables 383,000 -648,000 -49,000 -230,000 1.0M --
Change In Receivables 383,000 -644,000 174,000 -230,000 1.0M --
Change In Inventory -149,000 92,000 -1.1M 2.0M -912,000 --
Change In Payables And Accrued Expense 481,000 -450,000 1.0M -730,000 887,000 --
Change In Other Current Assets -9,000 -50,000 53,000 48,000 9,000 --
Other Non Cash Items -1.0M -225,000 -186,000 67,000 12,000 --
Capital Expenditure -46,000 -170,000 -66,000 -353,000 -832,000 --
Purchase Of PPE -46,000 -170,000 -66,000 -353,000 -832,000 --
Net PPE Purchase And Sale -46,000 -170,000 -66,000 -353,000 -754,000 --
Investing Cash Flow -821,000 -170,000 -66,000 -353,000 -754,000 --
Cash Flow From Continuing Investing Activities -821,000 -170,000 -66,000 -353,000 -754,000 --
Repayment Of Debt -118,000 -116,000 -116,000 -113,000 -110,000 --
Net Issuance Payments Of Debt -118,000 -116,000 -116,000 -113,000 -110,000 --
Repurchase Of Capital Stock -121,000 -59,000 -43,000 -77,000 -117,000 --
Net Common Stock Issuance -121,000 -59,000 -43,000 -77,000 -117,000 --
Common Stock Payments -121,000 -59,000 -43,000 -77,000 -117,000 --
Financing Cash Flow -239,000 -175,000 -159,000 -240,000 -227,000 --
Cash Flow From Continuing Financing Activities -239,000 -175,000 -159,000 -240,000 -227,000 --
Effect Of Exchange Rate Changes 11,000 -6,000 3,000 52,000 -17,000 --
Changes In Cash 113,000 -348,000 -738,000 783,000 -557,000 --
Beginning Cash Position 8.2M 8.5M 9.3M 8.4M 9.0M --
End Cash Position 8.3M 8.2M 8.5M 9.3M 8.4M --
Free Cash Flow 1.1M -173,000 -579,000 1.0M -408,000 --
Interest Paid Supplemental Data 6,000 8,000 8,000 10,000 11,000 --
Asset Impairment Charge 353,000 73,000 63,000 56,000 51,000 --
Depreciation -- 353,000 -- -- -- 304,000
Earnings Losses From Equity Investments 12,000 4,000 14,000 44,000 -4,000 --
Gain Loss On Investment Securities -- 18,000 -1,000 -- -- --
Gain Loss On Sale Of PPE 0.00 -- -- 0.00 -20,000 --
Long Term Debt Payments -118,000 -116,000 -116,000 -113,000 -110,000 --
Net Income From Continuing Operations 753,000 798,000 -932,000 -162,000 -1.0M --
Net Long Term Debt Issuance -118,000 -116,000 -116,000 -113,000 -110,000 --
Net Other Financing Charges -- -- -- -50,000 -- --
Net Other Investing Changes -775,000 -- -- 0.00 -- -912,000
Operating Gains Losses 12,000 22,000 13,000 -64,000 -24,000 --
Proceeds From Stock Option Exercised -- -- -- 0.00 0.00 --
Sale Of PPE 0.00 -- -- 0.00 78,000 --
NEWS
Loading news...
TRENDING
Loading...